Conventional isolated hyperthermic antiblastic perfusion in the treatment of recurrent limb melanoma

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 2017-2024

  Decian, Franco ^a   Mondini, Guido ^a   Demarchi, Roberto ^b   Muzio, Gianfranco ^a   Sementa, Angela ^b   Bocchio, Maria Maurizia ^a   Spirito, Carlo ^a   Simoni, Gianantonio ^a   Civalleri, Dario ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Hyperthermia; Melanoma; Perfusion; Treatment response

Indexed keywords

IODINE 125; MELPHALAN; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPERTHERMIC THERAPY; LIMB TUMOR; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; RECURRENT CANCER; SURGICAL TECHNIQUE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EXTRACORPOREAL CIRCULATION; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LEG; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; SURVIVAL RATE; TIME FACTORS;

EID: 0029740756     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Balch CM, Houghton A, Peters L: Cutaneous melanoma. In: "Cancer. Principle and practice in oncology", J.B. Lippincott (eds) Philadelphia, 1989, pp 1499.
2. Urist MM, Balch CM, Milton GW: Surgical management of the primary melanoma. In: "Cutaneous melanoma: clinical management and treatment results worldwide", J.B. Lippincott (eds) Philadelphia, 1983, pp 71.
3. Caseinelli N, Nava M, Vaglini M: Melanoma in Italy: experience at the National Cancer Institute of Milan. In: "Cutaneous melanoma: clinical management and treatment results worldwide", J.B. Lippincott (eds) Philadelphia 1985, pp 447.
4. Milton GW, Shaw HM, Farago GA: Tumour thickness and the site and the time of first recurrence in cutaneous malignant melanoma (stage I). Br J Surg 67: 543-546, 1980.
5. Lee Y-TM: Loco-regional primary and recurrent melanoma: III. Update of natural history and non-systemic treatments (1980-1987). Cancer Treat Rev 15: 135-162, 1988.
6. Markowitz JS, Cosimi LA, Carey RW, Kang S, Padyk C, Sober AJ, Cosimi AB: Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 126: 703-708, 1991.
7. Reintgen DS, Vollmer R, Tso CY, Seigler HF: Prognosis for recurrent stage I malignant melanoma. Arch Surg 122: 1338-1342, 1987.
8. Roses DF, Karp NS, Oratz R, Duhin N, Harris MN, Speyer J, Boyd A, Golomb FM, Ransohoff J, Dugan M, Valentine FT, Cooper J, Bystryn J-C: Survival with regional and distant metastases from cutaneous melanoma. Surg Gynecol Obstet 172: 262-268, 1991.
9. Brascho DJ: Radiotherapy for metastatic melanoma. In: "Cutaneous melanoma: clinical management and treatment results worldwide". J.B. Lippincott (cds) Philadelphia, 283, 1985.
10. Coates A: What can be expected from non surgical therapy? In: "Cutaneous melanoma biology and management", Masson (eds) Milano, 1990, pp 222.
11. Minutesor DR, Allen RE, Alberts D, Peng YM, Tardelli G, Hutchinson J: A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 55: 2638-2644, 1985.
12. Bland KI, Kimura AK, Brenner DE, Basinger MA, Hirsch M, Hawkins IF, Pierson KK, Copeland ME: A phase II study of the efficacy of diamminutesedichloroplatinum (Cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 209: 73-80, 1989.
13. Karakousis CP, Kanter PM, Lopez R: Modes of regional chemotherapy. J Surg Res 26: 134-141, 1979.
14. Karakousis CP. (1990) Intraarterial infusion in the management of melanoma of the limbs. In: "Cutaneous melanoma, biology and management", Masson (eds) Milano, 1990, pp 603.
15. Creech O, Krementz ET, Ryan RT, Winblad JN: Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148: 616-632, 1958.
16. Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, Mondovi B, Moricca G, Rossi-Fanelli A: Selective heat sensitivity of cancer cells. Cancer 20: 1351-1381, 1967.
17. Cavaliere R, Mondovi' B, Moricca G, Monticelli G, Natali PG, Santori S, Lopez M, DiFilippo F, Cavallari A, DeChiara N, Aiello R, Pantano FP, Proia G, Varanese A, Rossi Fanelli A: Trattamento ipertermico dei tumori: basi biochimiche, applicazioni sperimentali, risultati clinici. In: "L'ipertermia in terapia oncologica". Piccin (ed) Padova, 1981, 187-257.
18. Bull JMC: An update on the anticancer effects of a combination of chemotherapy and hyperthermia. Cancer Res (Suppl.) 44: 4853-4856, 1984.
19. Hornback NB: Hypertermia and Cancer. CRC Press Boca Raton, Florida, 164, 1984.
20. Luck JS, Murray J: Action of p-Di (2-chloroethyl)-amino-L-phenylalanine on Handing Passey mouse melanoma. Science 123: 948-985, 1956.
21. Stehlin JS jr, Giovanella BC, Delpolyi PD, Muenz LR, Anderson RF: Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 140: 339-348, 1975.
22. DiFilippo F, Giannarelli D, Citro C, Graziano F, Caroli S, Carlini S, Cavaliere F, Cavaliere R: Hyperthermic perfusion with CDDP. Standardization of treatment parameters. Fourth International Conference on Regional Cancer Treatment, Berchtesgaden, June 5-7, MP2, 1989.
23. Ghussen F, Kruger I, Groth W, Stutzer H: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 61: 654-659, 1988.
24. Hafström LO, Jönsson P-E: Hyperthermic perfusion of recurrent malignant melanoma of the extremities. Acta Chir Scand 146: 313-318, 1980.
25. Hafström LO, Jönsson P-E: Hyperthermic perfusion of recurrent malignant melanoma of the extremities. Cancer Treat Rep 68: 867-872, 1484.
26. Hafström LO, Rudenstam CM, Blomquist E, Ingvar C: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of extremities. J Clin Oncol 9(12): 2091-2094, 1991.
27. Hartley JW, Fletcher WS: Improved survival of patients with stage II melanoma of the extremity using hyperthermic isolation perfusion with 1-phenylalanine mustard. J Surg Oncol 26: 170-174, 1987.
28. Janoff KA, Moseson D, Nohlgren J, Davenport C, Richards C, Fletcher WS: The treatment of stage I melanoma of the extremities with regional hyperthermic isolation perfusion. Ann Surg 196: 316-323, 1982.
29. Klein ES e Ben-Hari GY: Isolation perfusion with cisplatin for malignant melanoma of the limbs. Cancer 59: 1068-1071, 1987.
30. 30) Krementz ET, Ryan RF, Carter RD, Sutherland CM, Reed RJ: Hyperthermic regional perfusion for melanoma of the limbs. In "Cutaneous melanoma. Clinical Management and Treatment Results Worldwide", J.B. Lippincott (eds), Philadelphia 1985, pp 171.
31. Krementz ET, Carter RD, Sutherland CM, Muchmorc JH: Chemotherapy by regional perfusion for limb melanoma. Am Surg 53: 133-140, 1987.
32. Lejeune FJ, Deloof T, Ewalenko P, Fruhling J, Jabri M, Mathieu M, Nogaret J-M, Verhest A: Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 86: 268-276, 1983.
33. Lejeune FJ, Lienard D, El Douaihy M, Seyedi JV, Ewalenko P: Results of 206 isolated limb perfusions for malignant melanoma. Eur J Surg Oncol 15(6): 510- 519, 1989.
34. Mikhail RA, Boddie AW, Ames FC, Zimmermann SO, McBride CM: Effect of variation of drug dosage on disease control and regional toxicity in prophylactic perfusion for stage I extremity melanoma. J Surg Oncol 27: 215-218, 1984.
35. Schraffordt-Koops H, Beekhuis H, Oldhoff J, Oosterhuis JW, Ploeg E, Vermey A: Local recurrence and survival in patients with (Clark level IV/V and over 1.5 mm thickness) stage I malignant melanoma of the extremities after regional perfusion. Cancer 48: 1952-1957, 1981.
36. Schraffordt-Koops H, Oldhoff J, Oosterhuis WJ: Isolated regional perfusion in malignant melanoma of the extremities. World J Surg 11: 527-533, 1987.
37. Stehlin JS, Giovanella BC, Delpolyi PD, Anderson RF: Results of hyperthermic perfusion for melanoma of the extremities. Cancer Res 39: 2255-2257, 1979.
38. Stehlin JS, Giovanella BC, Gutierrez AE, Delpolyi PD, Greef PJ: Fifteen years' experience with hyperthermic perfusion for treatment of soft tissue sarcoma and malignant melanoma of the extremities. Front Radiat Ther Oncol 18: 177-182, 1984.
39. Sutherland CM, Mather FJ, Krementz ET: Factors influencing survival in patients with regional melanoma of extremity treated by perfusion. Surg Gynecol Obstet 164: 111-118, 1987.
40. Tonak J, Hohenberger W, Weidner F, Gohl H: Hyperthermic perfusion in malignant melanoma: 5-year results. Recent Results Cancer Res 86: 229-238, 1983.
41. Vaglini M, Andreola S, Attili A, Belli F, Marolda R, Nava M, Prada A, Santinami M, Cascinelli N: Hyperthermic antiblastic perfusion in the treatment of cancer of the extremities. Tumori 71: 355-359, 1985.
42. De Cian F, Balletto N, Camerini G, De Paoli M, D'Aniello R, Ameri A, Brisighella A, Bonalumi U, Bachi V, Civalleri D: La perfusione isolata ipertermico-antiblastica per il melanoma avanzato degli arti. Tecnica, risultati immediati e revisione della letteratura. Min Chir 45(19): 1227-1237, 1990.
43. Wieberdink J, Benckhuysen C, Bratt RP, Van Slooten EA, Olthuis GAA: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18: 905-910, 1982.
44. International Union Against Cancer: Manual of cancer chemotherapy. Third Edition, UICC Technical Report Series 56: 1-25, 1981.
45. Didolkar MS, Fitzpatrick JL, Jackson AJ, Johnston GS: Toxicity and complications of vascular isolation and hyperthermic perfusion with Imidazole Carboxamide (DTIC) in melanoma. Cancer 57: 1961-1966, 1985.
46. Hafstrim LO, Hugander A, Jinsson P-E, Westling H, Ehrsson H: Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma. Cancer Treat Rep 68: 867-872, 1984.
47. Jönsson P-E, Hafström LO, Hugander A: Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities. Recent Results Cancer Res 86: 277-282, 1983.
48. Jönsson P-E., Hafström LO, Ingvar C, Olsson H, Jönsson N: Adjuvant regional hyperthermic perfusion versus no perfusion in high risk primary melanoma of the extremities. First International Conference on skin melanoma, Venice, May 6-9: 91, 1985.
49. Rege VB, Leone LA, Soderberg CH, Coleman GV, Robidoux HJ, Fijman R, Brown J: Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review. Cancer 52: 2033-2039, 1983.
50. Skene AI, Bulman AS, Williams TR, Thomas JM, Westbury G: Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 77: 765-767, 1990.
51. Storm FK, Morton DL: Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 150: 32-35, 1985.
52. Sugarbaker EV, McBride CM: Survival and regional disease control after isolation-perfusion for invasive stage I melanoma of the extremities. Cancer 37: 188-198, 1976.
53. Wagner DE: A retrospective study of regional perfusion for melanoma. Arch Surg 111: 410-413, 1976.
54. Ryan RF: Chemotherapy perfusion techniques and problems. Surg Clin North Am 42: 389-402, 1962.
55. Shiu MH, Knapper WH, Fortner JG, Yeh S, Horowitz G, Schnog J, Guerra J, Gould-Rossbach P, Ray C: Regional isolated limb perfusion of melanoma in transit metastases using mechlorethamin (Nitrogen Mustard). J Clin Oncol 4: 1819-1826, 1986.
56. Cornbleet MA, McElwait TJ, Kumar PJ: Treatment of advanced malignant melanoma with high dose melphalan and autologous bone marrow transplantation. Br J Cancer 48: 329-334, 1983.
57. DiFilippo F, Calabo A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F, Cavaliere R: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 63: 2551-2561, 1989.
58. Franklin HR, Schraffordt Koops H, Oldhoff J, Czarnetzky BM, Macher E, Kroon BBR, Welvaart K, Van der Velden JW, Van Dijk E, Van der Eseh EP, Oosterhuis JW, Huisman SJ, Hart AAM, Rümke P: To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm of greater. J Clin Oncol 6: 701-708, 1988.
59. Lejeune FJ and Ghanem EG: A simple and accurate new method for cytostatic dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res 47: 639-643, 1987.
60. Briele HA, Djuric M, Sung DT, Moertel T: Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 45: 1835-1889, 1985.
61. Boodie AW: A phase I study of melphalan in 40 °C isolated limb perfusion using packed red blood cells and lactated Ringer perfusate. Proc Am Soc Clin Oncol Annu Meet 11: 351, 1992.
62. Cavaliere F, Caroli S, Petrucci F, Alimonti S, Callopoli A, DiFilippo F: Hyperthermic perfusion with melphalan: a phase I study. Melanoma Res 3(Suppl 1): 94, 1993.
63. Pommier RF, Moseley HS, Cohen J, Huang CS, Townsend R-A, Fletcher WS: Pharmacokynetics, toxicity and short term results of cisplatin hyperthermic isolated limb perfusion for soft tissue sarcoma and melanoma of the extremities. Am J Surg 155: 667-671, 1988.
64. Hoekstra HJ, Schraffordt Koops HS, de Vriese IGE; Van Weerden TW, Oldhoff J: Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 72: 1224-1229, 1993.
65. Thompson JF, Gianoustos MP: Isolated limb perfusion for melanoma-effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16: 227-233, 1992.
66. Liènard D, Lejeune J, Ewalenko P: In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-τ and melphalan in isolation perfusion. World J Surg 16: 234-240, 1992.
67. Liènard D, Eggermont AMM, Schraffort Koops HS, Lejeune FJ: High dose of rTNFα rIFNτ and melphalan in isolation perfusion produces 90% CR in melanoma in transit metastases. Melanoma Res 3(Suppl 1):30, 1993.
68. Vaglini M, Santinami M, Manzi R, Inglese MG, Santoro N, Persiani L, Belli F: Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-α), melphalan and interferon (IFN-π). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 4: 35-8, 1994.
69. Bulman AS and Jamieson CW: Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg 67: 660-662, 1980.
70. Martijn H, Schraffordt-Koops H, Milton GW, Nap M, Oosterhuis JW, Shaw HM, Oldhoff J: Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion. Cancer 57: 1923-1930, 1986.